What is the clinical evidence from this study?

Study design: Other. Population: arterial occlusion. Intervention: chitosan nanocarrier (PNC) thrombolysis vs. standard-dose free tPA. Primary outcome: recanalization time.

What does this research mean for the field?

A low-dose targeted chitosan nanocarrier formulation achieves arterial recanalization times comparable to standard-dose free tPA while substantially reducing systemic fibrinogen depletion. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To develop a human-scale multiphysics model to quantitatively evaluate the performance, retention, and dosing strategies of targeted thrombolytic nanocarriers under clinically relevant arterial conditions.

September 28, 2026Materials Today AdvancesOpen Access

Multiphysics modeling of chitosan nanocarrier thrombolysis in human arterial occlusion: insights into carrier retention and dosing strategy

View Full Paper

Ask AI

Bookmark

Key result

Nanocarrier tPA matches standard recanalization times using ~10% the dose while reducing systemic fibrinogen depletion.

Why the study?

A human-scale multiphysics model is needed to comparatively evaluate thrombolytic nanocarrier performance and dosing strategies under clinically relevant arterial conditions.

Does a platelet-targeted nanocarrier containing tPA improve recanalization time and reduce systemic fibrinogen depletion compared to free tPA in a human-scale arterial occlusion model?

Comparison

Platelet-targeted nanocarrier containing tPA vs free tPA

Design

Coupled systemic pharmacokinetic-pharmacodynamic and one-dimensional convection-diffusion-reaction transport model

Authors

CLCailing LiPeking University YZYidan ZhangZhejiang Normal University XYXuehao YuYunnan Normal University

Discussion

Member takes

Implication

Model enables in silico nanocarrier testing; leaves open clinical translation for arterial thrombolysis.

Key Points

To develop a human-scale multiphysics model to quantitatively evaluate the performance, retention, and dosing strategies of targeted thrombolytic nanocarriers under clinically relevant arterial conditions.
Coupled a systemic pharmacokinetic-pharmacodynamic model with a one-dimensional convection-diffusion-reaction transport model in an occluded human artery.
Modeled platelet-triggered tissue plasminogen activator (tPA) release and formulation-specific binding to activated platelets across 22 scenarios varying thrombus composition, formulation, and dosing.
Platelet-targeted nanocarriers achieved shorter predicted recanalization times than free tPA in platelet-rich thrombi with sufficient activated platelet density.
Differences in clot retention and thrombolytic efficacy were governed by combined binding, release, transport, and pharmacokinetic parameters rather than diffusivity alone.
A single low-dose nanocarrier bolus of 10% standard tPA dose matched the recanalization time of standard-dose free tPA while substantially reducing modeled systemic fibrinogen depletion.

Structured PICO

Does a platelet-targeted nanocarrier containing tPA improve recanalization time and reduce systemic fibrinogen depletion compared to free tPA in a human-scale arterial occlusion model?

Population

22 simulated scenarios evaluating thrombus composition, nanocarrier formulation, and dosing regimens in a human-scale multiphysics model of arterial occlusion.

Intervention

Platelet-targeted nanocarrier (PNC) containing tissue plasminogen activator (tPA), including a single low-dose bolus containing 10% of standard tPA dose

Comparator

Free tPA (standard-dose bolus-plus-infusion regimen)

Outcome

Recanalization time and systemic fibrinogen depletionsurrogate

A computational multiphysics model suggests that a low-dose platelet-targeted tPA nanocarrier can achieve comparable recanalization to standard free tPA with less systemic fibrinogen depletion.

Cite This Study

Li et al. (2026) studied arterial occlusion. chitosan nanocarrier (PNC) thrombolysis vs. standard-dose free tPA was evaluated on recanalization time. A single low-dose chitosan nanocarrier bolus (10% of standard tPA dose) achieved recanalization times comparable to standard-dose free tPA with substantially less systemic fibrinogen depletion.

synapsesocial.com/papers/6ab9b43c7822ec8fc3d8d91f https://doi.org/10.1016/j.mtadv.2026.100993

View Full Paper

Ask AI

Bookmark

Multiphysics modeling of chitosan nanocarrier thrombolysis in human arterial occlusion: insights into carrier retention and dosing strategy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Multiphysics modeling of chitosan nanocarrier thrombolysis in human arterial occlusion: insights into carrier retention and dosing strategy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider